Kite Pharma, Inc. believes there is more room to lower its Yescarta turn-around time even after the US Food and Drug Administration approved a two-day reduction for its CAR-T cancer treatment Yescarta.
The manufacturing supplement that the FDA cleared will allow Kite’s median turn-around time for Yescarta (axicabtagene ciloleucel) to drop from 16 days to 14 days
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?